back to US directory
us clinical guidance

Distal symmetric polyneuropathy evaluation

A source-bounded AAN summary of laboratory and genetic testing in distal symmetric polyneuropathy; broader management remains blocked.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults with a length-dependent, symmetric sensory or sensorimotor neuropathy phenotype. The AAN laboratory and genetic-testing guideline is from 2009 but was reaffirmed in 2025. Acute inflammatory neuropathy, mononeuritis multiplex, motor-predominant disease, autonomic crisis, radiculopathy and focal entrapment require different and often urgent pathways.
sources for this section:AAN DSP 2009

The Bottom Line

  • Apply this page only after a clinician has established that the presentation fits distal symmetric polyneuropathy; the attached testing source does not provide a complete diagnostic-phenotyping pathway.
  • Prioritize high-yield testing for glucose dysregulation, vitamin B12 deficiency with metabolites when needed and serum protein immunofixation, then add tests only when phenotype and history support them.
  • Consider impaired-glucose-tolerance testing when routine glucose testing is not diagnostic and painful distal sensory neuropathy remains unexplained.
  • Use genetic testing when a hereditary neuropathy phenotype and inheritance or electrodiagnostic pattern support it; broad untargeted panels in cryptogenic disease without that phenotype have uncertain value.
sources for this section:AAN DSP 2009

Practical clinical workflow

1
Confirm that the clinical question is laboratory or genetic testing in an already characterized distal symmetric polyneuropathy; otherwise leave this narrow source and obtain the relevant exact authority.
2
Review prior glucose, vitamin B12 and monoclonal-protein evaluation and the phenotype or family history that would make targeted genetic testing relevant.
3
Order the source-supported high-yield laboratory tests and phenotype-directed genetic testing; this source does not establish when to perform electrodiagnostic studies.
4
Use separate exact current sources for etiologic treatment, foot protection, falls prevention and neuropathic-pain management; none of those operational pathways is established here.
sources for this section:AAN DSP 2009

Safety boundaries and escalation

  • The attached laboratory-and-genetic-testing guideline does not establish an emergency acute-neuropathy triage pathway; attach an exact current source before publishing actionable escalation instructions.
  • It also does not establish electrodiagnostic indications for asymmetric, motor-predominant, autonomic or otherwise atypical neuropathy.
  • It does not establish ulcer, Charcot, ischemic-foot, falls or limb-protection management; those questions require their own exact authorities.
  • Reaffirmation in 2025 confirms the narrow testing document remains listed; it does not expand that document into a comprehensive neuropathy guideline.
sources for this section:AAN DSP 2009

Localization

The AAN/AANEM/AAPM&R source is older but explicitly reaffirmed in 2025. It supports targeted laboratory and genetic testing only; it is not evidence for electrodiagnosis, treatment, foot care, falls care or pain prescribing.
sources for this section:AAN DSP 2009

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and RehabilitationEvaluation of Distal Symmetric Polyneuropathy: Role of Laboratory and Genetic Testing2009 practice guideline; reaffirmed 2025-02-08 路 published 2009-01-01 路 updated 2025-02-08 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.